<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099255</url>
  </required_header>
  <id_info>
    <org_study_id>SG030-0004</org_study_id>
    <nct_id>NCT00099255</nct_id>
    <nct_alias>NCT00118079</nct_alias>
  </id_info>
  <brief_title>Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma</brief_title>
  <official_title>A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <brief_summary>
    <textblock>
      This multi-center, phase II study will be conducted to define the toxicity profile and&#xD;
      antitumor activity of SGN-30 in patients with pcALCL and other closely related&#xD;
      lymphoproliferative disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the objective response rate in patients with pcALCL, T-MF, and LyP</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the duration of response in patients treated with SGN-30</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the toxicity profile of SGN-30</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide preliminary estimates of disease-free and overall survival rates in pcALCL and T-MF patients treated with SGN-30</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the immunogenicity of SGN-30</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Large Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-30</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients must have a definite diagnosis.&#xD;
&#xD;
          -  Patients must be histologically confirmed CD30 positive within 3 months of enrollment&#xD;
&#xD;
          -  Patients with pcALCL must have target lesions present for at least 1 month without&#xD;
             spontaneous regression&#xD;
&#xD;
          -  pcALCL patients must have failed treatment with local radiation therapy, or failed&#xD;
             systemic therapy of a single agent&#xD;
&#xD;
          -  Patients must be considered an eligible candidate for systemic therapy as determined&#xD;
             by the investigator&#xD;
&#xD;
          -  All patients must have a three week wash-out from previous treatments, unless in the&#xD;
             opinion of the investigator it is not in the best interest of the patient, at which&#xD;
             point the individual case must be discussed with the medical monitor prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients must have an ECOG performance status of &lt; 2 (Appendix B) and a life&#xD;
             expectancy &gt; six months.&#xD;
&#xD;
          -  Patients must be at least 18 years of age.&#xD;
&#xD;
          -  Patients must be available for periodic blood sampling, study-related assessments, and&#xD;
             management of toxicity at the treating institution.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative HCG pregnancy test result&#xD;
             within three days of enrollment. All patients must agree to use an effective&#xD;
             contraceptive method during the course of the study.&#xD;
&#xD;
          -  Patients must give written informed consent.&#xD;
&#xD;
          -  Required baseline laboratory data: Absolute neutrophil count greater than or equal to&#xD;
             to 1,000/mm3, Platelet count greater than or equal to 75,000/mm3, Serum bilirubin less&#xD;
             than or equal to 1.5 times ULN, Serum creatinine less than or equal to 1.5 times ULN,&#xD;
             BUN less than or equal to 1.5 times ULN, SGOT less than or equal to 2.5 ULN, SGPT less&#xD;
             than or equal to 2.5 ULN&#xD;
&#xD;
        Criteria for Exclusion&#xD;
&#xD;
          -  Patients with Sezary syndrome, or any type of lymphoproliferative disease other than&#xD;
             pcALCL, T-MF or LyP&#xD;
&#xD;
          -  Patients with systemic ALCL or extracutaneous involvement of cutaneous ALCL&#xD;
&#xD;
          -  Patients with known active systemic viral, bacterial, or fungal infection&#xD;
&#xD;
          -  Patients who are known to be HIV, Hepatitis B, or Hepatitis C positive&#xD;
&#xD;
          -  Patients who have been treated previously with any anti-CD30 antibody&#xD;
&#xD;
          -  Patients with a known hypersensitivity to recombinant proteins or any excipient&#xD;
             contained in the drug formulation&#xD;
&#xD;
          -  Patients with a history of other malignancies during the past five years with the&#xD;
             exception of adequately treated basal or squamous cell skin cancer or cervical&#xD;
             carcinoma in situ&#xD;
&#xD;
          -  Patients with symptomatic cardiac disease including ventricular dysfunction, coronary&#xD;
             artery disease, or arrhythmias&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding&#xD;
&#xD;
          -  Patients with any serious underlying medical condition that would impair their ability&#xD;
             to receive or tolerate the planned treatment&#xD;
&#xD;
          -  Patients with dementia or altered mental status that would preclude understanding and&#xD;
             rendering of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Universtiy</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Oncology Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alcl.com/</url>
    <description>Anaplastic Large Cell Lymphoma resource site</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19789316</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009 Oct 1;15(19):6217-24. doi: 10.1158/1078-0432.CCR-09-0162. Epub 2009 Sep 29.</citation>
    <PMID>19789316</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 10, 2004</study_first_submitted>
  <study_first_submitted_qc>December 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2004</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <keyword>Keyword?</keyword>
  <keyword>Primary Cutaneous Anaplastic Large Cell Lymphoma</keyword>
  <keyword>Large Cell Transformation of Mycosis Fungoides</keyword>
  <keyword>Lymphomatoid Papulosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphomatoid Papulosis</mesh_term>
    <mesh_term>Lymphoma, Primary Cutaneous Anaplastic Large Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

